Latest Articles

Publication Date
All News Scientific
Diagnostic role of galanin in distinguishing endometrial atypical hyperplasia and carcinoma from benign endometrial conditions - Nature

Diagnostic role of galanin in distinguishing endometrial atypical hyperplasia and carcinoma from benign endometrial conditions Nature

Published: Oct. 27, 2025, 2:48 p.m.
Read Full Article
Primary Invasive Squamous Cell Carcinoma of the Vagina Presenting Three Decades After Total Hysterectomy for Benign Endometriosi - Cureus

Primary Invasive Squamous Cell Carcinoma of the Vagina Presenting Three Decades After Total Hysterectomy for Benign Endometriosi Cureus

Published: Oct. 24, 2025, 12:29 a.m.
Read Full Article
Primary Invasive Squamous Cell Carcinoma of the Vagina Presenting Three Decades After Total Hysterectomy for Benign Endometriosis: A Case Report - Cureus

Primary Invasive Squamous Cell Carcinoma of the Vagina Presenting Three Decades After Total Hysterectomy for Benign Endometriosis: A Case Report Cureus

Published: Oct. 23, 2025, 6:10 p.m.
Read Full Article
Shifted assembly and function of mSWI/SNF family subcomplexes underlie targetable dependencies in dedifferentiated endometrial carcinomas - Nature

Shifted assembly and function of mSWI/SNF family subcomplexes underlie targetable dependencies in dedifferentiated endometrial carcinomas Nature

Published: Oct. 20, 2025, 9:19 a.m.
Read Full Article
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - The AI Journal

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen The AI Journal

Published: Oct. 18, 2025, 10:28 a.m.
Read Full Article
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - Business Wire

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen Business Wire

Published: Oct. 18, 2025, 10 a.m.
Read Full Article
Two Cases of Mesonephric-Like Adenocarcinoma Arising From Ovary and Peritoneal and Literature Review - Cureus

Two Cases of Mesonephric-Like Adenocarcinoma Arising From Ovary and Peritoneal and Literature Review Cureus

Published: Oct. 12, 2025, 2:15 p.m.
Read Full Article
Can IVIM MRI be superior to ADC in predicting aggressive subtypes of endometrial carcinoma: new insights into FIGO 2023 classification - SpringerOpen

Can IVIM MRI be superior to ADC in predicting aggressive subtypes of endometrial carcinoma: new insights into FIGO 2023 classification SpringerOpen

Published: Oct. 10, 2025, 6:31 a.m.
Read Full Article
Distinct genomic subgroups and mutational patterns in undifferentiated/dedifferentiated endometrial carcinoma - BMC Cancer

Distinct genomic subgroups and mutational patterns in undifferentiated/dedifferentiated endometrial carcinoma BMC Cancer

Published: Oct. 9, 2025, 1:10 p.m.
Read Full Article
ACOXL-AS1’s pan-cancer dynamics and its proliferative impact on endometrial endometrioid carcinoma - BMC Cancer

ACOXL-AS1’s pan-cancer dynamics and its proliferative impact on endometrial endometrioid carcinoma BMC Cancer

Published: Oct. 6, 2025, 2:30 p.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!